-
. You will use human in vitro models, including astrocytes and brain organoids generated from induced pluripotent stem cells (iPSCs) of people with MLC and healthy controls. You will investigate disease
-
physiologically relevant human in vitro model of Pelizaeus-Merzbacher-like disease type 1 (PMLD1). You will first test leading AAV capsids developed by Myrtelle Therapeutics Inc. in the in vitro model. You will
-
liquid biomarkers for leukodystrophies by integrating multi-omics data from patient plasma and iPSC-derived human disease models. You will investigate disease-related molecular signatures using
-
plasma and iPSC-derived human disease models. You will investigate disease-related molecular signatures using metabolomics, lipidomics, proteomics and genomics, and combine these data using statistical and
-
This doctoral project focuses on establishing isogenic iPSC-derived myelinating organoids as a physiologically relevant human in vitro model of Pelizaeus-Merzbacher-like disease type 1 (PMLD1). You will first
-
, for example through newborn screening, family screening or genetic testing. These families may face uncertainty about when symptoms will develop and difficult decisions about treatment. Understanding
-
. These families may face uncertainty about when symptoms will develop and difficult decisions about treatment. Understanding their experiences and support needs is important for developing patient-centred screening
-
salary here . Holiday hours: 194.4 per year for full time and a possibility to save additional hours. 100% reimbursement for public transport travel costs. If you travel by foot, bicycle, or car, a mileage